NY‐ESO‐1: Review of an Immunogenic Tumor Antigen
Section snippets
Name and Family History
The etymology of NY‐ESO‐1 tells the story of its origins: NY stands for the city in which it was discovered by Chen et al. (1997), at the Ludwig Institute for Cancer Research and Weill Medical College of Cornell University in New York, in 1997; ESO is for esophageal cancer where it was originally described by screening a tumor‐derived cDNA expression library with autologous serum of an esophageal cancer patient; and this was the first member of a new gene family.
The gene coding for NY‐ESO‐1,
Indications and Usage: Expression of NY‐ESO‐1 in Tumor Cells
The promise of NY‐ESO‐1 as a candidate for specific immune recognition of cancer comes from its restricted expression in normal tissues but frequent occurrence in cancer. Although originally described from the cDNA sequences of an esophageal tumor, NY‐ESO‐1 has shown a much more widespread incidence in a number of other tumor types. The expression of NY‐ESO‐1 has been analyzed in surgically removed primary or metastatic cancer tissues on two levels: message by RT‐PCR and protein by
Concluding Remarks
Knowing what to expect is not a luxury when planning immunotherapeutic intervention, and NY‐ESO‐1 with its strong inherent immunogenicity in a subset of cancer patients has set the standards to reach. With a booming number of clinical trials with NY‐ESO‐1 as a model antigen, clinical correlations of immunogenicity and patient benefit, if any, should soon be established. Current vaccines still have a lot of room for improvement, both in antigen and in adjuvant formulations. An efficient vaccine
Acknowledgments
We are grateful to Ramon Chua and Bernadette Keitz for their help in generating and compiling the RT‐PCR data.
Financial Support: Supported by the Cancer Vaccine Collaborative funded by the Cancer Research Institute and Ludwig Institute for Cancer Research.
References (109)
- et al.
A new member of the NY‐ESO‐1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved
Gene
(2002) - et al.
Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC
J. Immunol. Methods
(2003) - et al.
The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling
Cell
(2005) - et al.
Cancer/testis tumour‐associated antigens: Immunohistochemical detection with monoclonal antibodies
Lancet Oncol.
(2003) - et al.
CD4+ CD25+ regulatory T cells control the induction of antigen‐specific CD4+ helper T cell responses in cancer patients
Blood
(2005) - et al.
hMAGE‐A1 overexpression reduces TNF‐alpha cytotoxicity in ME‐180 cells
Mol. Cells
(2002) - et al.
Expression of cancer/testis (CT) antigens in chinese hepatocellular carcinoma and its correlation with clinical parameters
Cancer Lett.
(2005) - et al.
The cancer‐testis gene, NY‐ESO‐1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ
Lab. Invest.
(2002) - et al.
Expression of cancer/testis (CT) antigens in lung cancer
Lung Cancer
(2003) - et al.
NY‐ESO‐1 is highly expressed in poor‐prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
Blood
(2005)
Tumor‐specific human CD4+ regulatory T cells and their ligands: Implications for immunotherapy
Immunity
Interleukin‐2‐induced, melanoma‐specific T cells recognize CAMEL, an unexpected translation product of LAGE‐1
Int. J. Cancer
NY‐ESO‐1 expression and its serum immunoreactivity in esophageal cancer
Cancer Chemother. Pharmacol.
Dendritic cells acquire antigen from apoptotic cells and induce class I‐restricted CTLs
Nature
The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma
Cancer Immun.
Comprehensive analysis of the frequency of recognition of melanoma‐associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): Implications for immunotherapy
Eur. J. Immunol.
Major histocompatibility complex class II‐positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells
J. Exp. Med.
NY‐ESO‐1/LAGE‐1 coexpression with MAGE‐A cancer/testis antigens: A tissue microarray study
Int. J. Cancer
Expression of tumor‐specific cancer/testis antigens in hepatocellular carcinoma
Zhonghua Gan Zang Bing Za Zhi
Identification of NY‐ESO‐1 peptide analogues capable of improved stimulation of tumor‐reactive CTL
J. Immunol.
Structural and kinetic basis for heightened immunogenicity of T cell vaccines
J. Exp. Med.
Immunodominant CD4+ responses identified in a patient vaccinated with full‐length NY‐ESO‐1 formulated with ISCOMATRIX adjuvant
Proc. Natl. Acad. Sci. USA
Characterization of antigen‐specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination
Cancer Immun.
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
Proc. Natl. Acad. Sci. USA
A member of the GAGE family of tumor antigens is an anti‐apoptotic gene that confers resistance to Fas/CD95/APO‐1, interferon‐gamma, taxol and gamma‐irradiation
Cancer Biol. Ther.
Autoreactive T cells in healthy individuals
J. Immunol.
Recombinant NY‐ESO‐1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans
Proc. Natl. Acad. Sci. USA
The activation of human gene MAGE‐1 in tumor cells is correlated with genome‐wide demethylation
Proc. Natl. Acad. Sci. USA
Expression of cancer/testis (CT) antigens MAGE‐A1, MAGE‐A3, MAGE‐A4, CT‐7, and NY‐ESO‐1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease
Cancer Immun.
Functional avidity of tumor antigen‐specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR
J. Immunol.
Multiepitope CD8(+) T cell response to a NY‐ESO‐1 peptide vaccine results in imprecise tumor targeting
J. Clin. Invest.
NY‐ESO‐1 protein expression and humoral immune responses in prostate cancer
Prostate
NY‐ESO‐1 expression and immunogenicity in esophageal cancer
Clin. Cancer Res.
Human gene MAGE‐3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
J. Exp. Med.
Strategy for monitoring T cell responses to NY‐ESO‐1 in patients with any HLA class I allele
Proc. Natl. Acad. Sci. USA
CD8+ T cell responses against a dominant cryptic HLA‐A2 epitope after NY‐ESO‐1 peptide immunization of cancer patients
Proc. Natl. Acad. Sci. USA
Survey of naturally occurring CD4+ T cell responses against NY‐ESO‐1 in cancer patients: Correlation with antibody responses
Proc. Natl. Acad. Sci. USA
Cross‐presentation of HLA class I epitopes from exogenous NY‐ESO‐1 polypeptides by nonprofessional APCs
J. Immunol.
Medullary epithelial cells of the human thymus express a highly diverse selection of tissue‐specific genes colocalized in chromosomal clusters
J. Exp. Med.
Cancer‐testis genes are coordinately expressed and are markers of poor outcome in non‐small cell lung cancer
Clin. Cancer Res.
HLA‐DP4 expression and immunity to NY‐ESO‐1: Correlation and characterization of cytotoxic CD4+ CD25‐ CD8‐ T cell clones
Cancer Immun.
The central role of CD4(+) T cells in the antitumor immune response
J. Exp. Med.
Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self‐peptide
Nat. Immunol.
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY‐ESO‐1 but not MAGE‐A1 or CT7
Int. J. Cancer
Meeting abstract
Mod. Pathol.
Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues
Int. J. Cancer
Meeting abstract
Pathol. Res. Pract.
Urine antibody against human cancer antigen NY‐ESO‐1
Cancer Immun.
Simultaneous humoral and cellular immune response against cancer‐testis antigen NY‐ESO‐1: Definition of human histocompatibility leukocyte antigen (HLA)‐A2‐binding peptide epitopes
J. Exp. Med.
Humoral immune responses of cancer patients against “Cancer‐Testis” antigen NY‐ESO‐1: Correlation with clinical events
Int. J. Cancer
Cited by (306)
Advances in dendritic cell vaccination therapy of cancer
2023, Biomedicine and PharmacotherapyCRISPR/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study
2022, International ImmunopharmacologyCancer immunotherapy via nucleic acid aptamers
2022, Aptamers Engineered Nanocarriers for Cancer Therapy